Table 4.
Characteristics of patients with tumors harboring one or more of 30 gene fusions with oncogenic potential.
| Tumor samples N = 24 |
No. fusions detected per sample | Fusions detected in each sample | Patient characteristics | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | Sex | MGMT promoter methylation? | Type of glioma | Survival (months) | G-CIMP? | IDH1 mutations? (by IHC) |
TCGA subtype | IGS subtype | |||
| AC0340 | 1 | PID1::DNERa | 67 | Man | No | Primary | 7.62 | No | No | Pro | 9 |
| AC0346 | 1 | ACVR1B::SCAF11a | 50 | Man | Yes | Secondary | 30.49 | Yes | Yes | Pro | 9 |
| AC0365 | 1 | CNOT2::RBMS2a | 71 | Man | Yes | Primary | 10.61 | No | No | Pro | 17 |
| AC6287 | 1 | NUDT3::MAP4a | 48 | Man | Yes | Primary | 27.86 | No | NA | Cla | 18 |
| AA6367 | 2 | ZMPSTE24::CACNA1DaADD2::C2orf42a | 53 | Woman | No | Primary | 4.53 | No | No | Cla | 18 |
| AC6255 | 1 | AVIL::CPMa | 77 | Man | Yes | Primary | 21.36 | No | No | Mes | 18 |
| AC6246 | 1 | TSFM::KIF5Aa | 65 | Woman | No | Primary | 12.98 | No | No | Pro | 0 |
| AC6253 | 1 | PDIA5::IQCB1a | 73 | Man | Yes | Primary | 9.69 | No | No | Mes | 23 |
| AC6237 | 1 | LAMA5::PSMD3a | 71 | Woman | Yes | Primary | 4.30 | No | No | Cla | 18 |
| AC6281 | 1 | KIF5A::AVILa | 79 | Man | Yes | Primary | 2.79 | No | No | Pro | 9 |
| AC6282 | 1 | WSB1::SEZ6a | 64 | Woman | No | Primary | 8.74 | No | No | Pro | 18 |
| AA6373 | 1 | PIK3CB::EPHB1b | 54 | Man | No | Primary | 24.15 | No | No | Pro | 18 |
| AA6366 | 1 | TBK1::TMPRSS12b | 79 | Man | No | Primary | 16.30 | No | No | Mes | 18 |
| AC6276 | 1 | CREB5::ABCA13b | 78 | Man | Yes | Primary | 8.15 | No | No | Cla | 18 |
| AA6380 | 4 |
AGAP2::KIF5Ac EGFR::R3HDM2c USP22::TMC3c KCNMB4::Ca |
61 | Man | Yes | Primary | 36.50 | No | No | Pro | 22 |
| AC0344 | 1 | CEP78::GNAQc | 57 | Man | Yes | Primary | 26.18 | No | No | Cla | 18 |
| AA6364 | 1 | EGFR::SEPTIN14d | 55 | Woman | Yes | Primary | 42.55 | NA | No | NA | NA |
| AC0438 | 1 | EGFR::SEPTIN14d | 62 | Woman | Yes | Primary | 21.13 | No | No | Cla | 18 |
| AC0364 | 3 |
CLIC4::SRRM1d DPYSL3::JAKMIP2c ABL1::SZRD1c |
62 | Woman | No | Secondary | 12.65 | No | No | Cla | 18 |
| AC6239 | 1 | CAPZA2::METd | 80 | Man | No | Primary | 1.51 | No | No | Pro | 9 |
| AA6397 | 1 | FGFR3::TACC3d | 63 | Man | No | Primary | 32.89 | No | No | Cla | 18 |
| AC6283 | 1 | FGFR3::TACC3d | 70 | Man | No | Primary | 9.76 | No | NA | Cla | 18 |
| AC2104 | 3 |
FGFR3::TACC3d CTDSP2-GLI1c CTDSP2::INHBEa |
75 | Man | Yes | Primary | 30.82 | No | No | Cla | 18 |
| AA6386 | 2 |
SEC61G::EGFRd CALD1-ADAM22a |
70 | Woman | No | Primary | 10.81 | No | No | Pro | 18 |
IHC immunohistochemistry, Pro proneural, Cla classical, Mes mesenchymal, NA not available.
aIn-frame fusion that can produce a protein but that has not previously been described in cancer, does not involve an oncogene or tumor suppressor gene, and was not predicted to have oncogenic potential by Oncofuse.
bFusion predicted by Oncofuse to have oncogenic potential.
cFusion not previously described in cancer but involving an oncogene or tumor suppressor gene.
dFusion previously described in cancer.